Valeo Financial Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Valeo Financial Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5	Closed	–	–	1925
2021 Q1	$0	Hold	5	–	–	﹤0.01%	2223
2020 Q4	$0	Hold	5	–	–	﹤0.01%	1898
2020 Q3	$0	Hold	5	–	–	﹤0.01%	2205
2020 Q2	$0	Hold	5	–	–	﹤0.01%	2186
2020 Q1	$0	Hold	5	–	–	﹤0.01%	1949
2019 Q4	$0	Hold	5	–	–	﹤0.01%	1745
2019 Q3	$0	Hold	5	–	–	﹤0.01%	1704
2019 Q2	$0	Hold	5	–	–	﹤0.01%	1681
2019 Q1	$0	Hold	5	–	–	﹤0.01%	1653
2018 Q4	$0	Hold	5	–	–	﹤0.01%	1767
2018 Q3	$0	Hold	5	–	–	﹤0.01%	1884
2018 Q2	$0	Hold	5	–	–	﹤0.01%	1781
2018 Q1	$0	Hold	5	–	–	﹤0.01%	1617
2017 Q4	$0	Hold	5	–	–	﹤0.01%	1441
2017 Q3	$0	Buy	+5	New	+$302	﹤0.01%	1191

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Valeo Financial Advisors's EGRX Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2021, closing a stake of 5 shares.

Valeo Financial Advisors first reported a position in EGRX in Q3 2017 and held it in 15 quarters. The position peaked at $0 in Q1 2021. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

Valeo Financial Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Valeo Financial Advisors sold 5 Eagle Pharmaceuticals, Inc. shares in Q2 2021.
Valeo Financial Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 15 quarters.
Valeo Financial Advisors's Eagle Pharmaceuticals, Inc. position peaked at $0 in Q1 2021.
146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.